Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PMID:
31495780
2.

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.

Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR.

Cell Rep. 2019 Sep 3;28(10):2728-2738.e7. doi: 10.1016/j.celrep.2019.07.106.

3.

Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

Balanis NG, Sheu KM, Esedebe FN, Patel SJ, Smith BA, Park JW, Alhani S, Gomperts BN, Huang J, Witte ON, Graeber TG.

Cancer Cell. 2019 Jul 8;36(1):17-34.e7. doi: 10.1016/j.ccell.2019.06.005.

PMID:
31287989
4.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
5.

T cell antigen discovery via trogocytosis.

Li G, Bethune MT, Wong S, Joglekar AV, Leonard MT, Wang JK, Kim JT, Cheng D, Peng S, Zaretsky JM, Su Y, Luo Y, Heath JR, Ribas A, Witte ON, Baltimore D.

Nat Methods. 2019 Feb;16(2):183-190. doi: 10.1038/s41592-018-0305-7. Epub 2019 Jan 28.

6.

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A.

Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.

PMID:
30409823
7.

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10702-E10711. doi: 10.1073/pnas.1810653115. Epub 2018 Oct 22.

8.

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON.

Science. 2018 Oct 5;362(6410):91-95. doi: 10.1126/science.aat5749.

9.

A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers.

Smith BA, Balanis NG, Nanjundiah A, Sheu KM, Tsai BL, Zhang Q, Park JW, Thompson M, Huang J, Witte ON, Graeber TG.

Cell Rep. 2018 Sep 18;24(12):3353-3366.e5. doi: 10.1016/j.celrep.2018.08.062.

10.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

11.

18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.

Salas JR, Chen BY, Wong A, Cheng D, Van Arnam JS, Witte ON, Clark PM.

J Nucl Med. 2018 Oct;59(10):1616-1623. doi: 10.2967/jnumed.118.210328. Epub 2018 Apr 26.

12.

Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.

Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. doi: 10.1073/pnas.1802354115. Epub 2018 Apr 23.

13.

Noninvasive Imaging of Drug-Induced Liver Injury with 18F-DFA PET.

Salas JR, Chen BY, Wong A, Duarte S, Angarita SAK, Lipshutz GS, Witte ON, Clark PM.

J Nucl Med. 2018 Aug;59(8):1308-1315. doi: 10.2967/jnumed.117.206961. Epub 2018 Mar 1.

14.

FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.

Park JW, Lee JK, Witte ON, Huang J.

Mod Pathol. 2017 Sep;30(9):1262-1272. doi: 10.1038/modpathol.2017.44. Epub 2017 Jun 16.

15.

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL.

Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M.

J Exp Med. 2017 Mar 6;214(3):793-814. doi: 10.1084/jem.20160049. Epub 2017 Feb 11.

16.

Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.

Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS.

Cell Rep. 2016 Dec 6;17(10):2596-2606. doi: 10.1016/j.celrep.2016.11.010.

17.

Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. Epub 2016 Sep 30.

18.

Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.

Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM.

Cell. 2016 Aug 11;166(4):1041-1054. doi: 10.1016/j.cell.2016.07.007. Epub 2016 Aug 4.

19.

Advances in PET Detection of the Antitumor T Cell Response.

McCracken MN, Tavaré R, Witte ON, Wu AM.

Adv Immunol. 2016;131:187-231. doi: 10.1016/bs.ai.2016.02.004. Epub 2016 Apr 5. Review.

20.

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.

Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31.

21.

Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.

Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7. doi: 10.1073/pnas.1603645113. Epub 2016 Apr 4.

22.

[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4027-32. doi: 10.1073/pnas.1524212113. Epub 2016 Mar 28.

23.

Tissue Recombination Models for the Study of Epithelial Cancer.

Zong Y, Goldstein AS, Witte ON.

Cold Spring Harb Protoc. 2015 Dec 2;2015(12):pdb.top069880. doi: 10.1101/pdb.top069880.

PMID:
26631129
24.

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30.

25.

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM.

Cancer Res. 2016 Jan 1;76(1):73-82. doi: 10.1158/0008-5472.CAN-15-1707. Epub 2015 Nov 16.

26.

Lift NIH restrictions on chimera research.

Sharma A, Sebastiano V, Scott CT, Magnus D, Koyano-Nakagawa N, Garry DJ, Witte ON, Nakauchi H, Wu JC, Weissman IL, Wu SM.

Science. 2015 Nov 6;350(6261):640. doi: 10.1126/science.350.6261.640-a. Epub 2015 Nov 5. No abstract available.

27.

Dissociated Prostate Regeneration under the Renal Capsule.

Zong Y, Goldstein AS, Witte ON.

Cold Spring Harb Protoc. 2015 Nov 2;2015(11):991-4. doi: 10.1101/pdb.prot078063.

PMID:
26527760
28.

Preparation of Urogenital Sinus Mesenchymal Cells for Prostate Tissue Recombination Models.

Zong Y, Goldstein AS, Witte ON.

Cold Spring Harb Protoc. 2015 Nov 2;2015(11):988-90. doi: 10.1101/pdb.prot078055.

PMID:
26527759
29.

A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, Mathis C, Cheng D, Stuart JM, Witte ON.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6544-52. doi: 10.1073/pnas.1518007112. Epub 2015 Oct 12.

30.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

31.

Development of 2-Deoxy-2-[(18)F]fluororibose for Positron Emission Tomography Imaging Liver Function in Vivo.

Evdokimov NM, Clark PM, Flores G, Chai T, Faull KF, Phelps ME, Witte ON, Jung ME.

J Med Chem. 2015 Jul 23;58(14):5538-47. doi: 10.1021/acs.jmedchem.5b00569. Epub 2015 Jul 2.

32.

Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.

Tavaré R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM.

J Nucl Med. 2015 Aug;56(8):1258-64. doi: 10.2967/jnumed.114.153338. Epub 2015 May 7.

33.

Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.

McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON.

J Clin Invest. 2015 May;125(5):1815-26. doi: 10.1172/JCI77326. Epub 2015 Mar 30.

34.

Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells.

Smith DJ, Liu S, Ji S, Li B, McLaughlin J, Cheng D, Witte ON, Yang L.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1523-8. doi: 10.1073/pnas.1424877112. Epub 2015 Jan 20.

35.

Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.

Bunimovich YL, Nair-Gill E, Riedinger M, McCracken MN, Cheng D, McLaughlin J, Radu CG, Witte ON.

PLoS One. 2014 Aug 7;9(8):e104125. doi: 10.1371/journal.pone.0104125. eCollection 2014.

36.

HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.

Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB.

Cancer Res. 2014 Sep 15;74(18):5173-83. doi: 10.1158/0008-5472.CAN-14-0376. Epub 2014 Jul 18.

37.

Positron emission tomography probe demonstrates a striking concentration of ribose salvage in the liver.

Clark PM, Flores G, Evdokimov NM, McCracken MN, Chai T, Nair-Gill E, O'Mahony F, Beaven SW, Faull KF, Phelps ME, Jung ME, Witte ON.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2866-74. doi: 10.1073/pnas.1410326111. Epub 2014 Jun 30.

38.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

39.

Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Drake JM, Lee JK, Witte ON.

Mol Cell Biol. 2014 May;34(10):1722-32. doi: 10.1128/MCB.01592-13. Epub 2014 Feb 24. Review.

40.

Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.

Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, Witte ON, Wu AM.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13. doi: 10.1073/pnas.1316922111. Epub 2014 Jan 3.

41.

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON, Goldstein AS.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20111-6. doi: 10.1073/pnas.1320565110. Epub 2013 Nov 26.

42.

Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.

Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9. doi: 10.1073/pnas.1319948110. Epub 2013 Nov 18.

43.

Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON, Kayadibi H, Ryan CM, Jung ME, Faull K, Memarzadeh S.

Mol Cancer Ther. 2013 Dec;12(12):2917-28. doi: 10.1158/1535-7163.MCT-13-0572. Epub 2013 Nov 12.

44.

Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros.

Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE, Lawson GW, Bensinger SJ, Farnham PJ, Witte ON, Smale ST.

Nat Immunol. 2013 Oct;14(10):1073-83. doi: 10.1038/ni.2707. Epub 2013 Sep 8.

45.

Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity.

Zangle TA, Burnes D, Mathis C, Witte ON, Teitell MA.

PLoS One. 2013 Jul 23;8(7):e68916. doi: 10.1371/journal.pone.0068916. Print 2013.

46.

Does the microenvironment influence the cell types of origin for prostate cancer?

Goldstein AS, Witte ON.

Genes Dev. 2013 Jul 15;27(14):1539-44. doi: 10.1101/gad.222380.113.

47.

Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues.

Smith DA, Kiba A, Zong Y, Witte ON.

Mol Cancer Res. 2013 Oct;11(10):1159-65. doi: 10.1158/1541-7786.MCR-13-0238. Epub 2013 Jul 18.

48.

Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, Iruela-Arispe ML, Memarzadeh S.

Cancer Res. 2013 Aug 1;73(15):4697-710. doi: 10.1158/0008-5472.CAN-13-0930. Epub 2013 Jun 6.

49.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR.

Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21.

50.

Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, Gjertson D, Baltimore D, Witte ON, Economou JS, Ribas A, Kohn DB.

Mol Ther. 2013 May;21(5):1044-54. doi: 10.1038/mt.2013.8. Epub 2013 Feb 5.

Supplemental Content

Loading ...
Support Center